UoA 1. Clinical Medicine – 4* impact case studies

Delivering better birthdays: research-based training programme makes labour and birth safer for babies and mothers across the world (University of Bristol)

Expressed hERG potassium channel bioassays in mammalian cell lines to evaluate safety and efficacy of new drugs (University of Bristol)

Health benefits, increased public awareness and changes in national policy result from the successful implantation of the first tissue-engineered trachea, created utilising the patient’s own stem cells (University of Bristol)

Lower risks to patients, advances in international practice and substantial resource savings result from ‘beating heart’ off-pump coronary artery bypass surgery (University of Bristol)

Minimal residual disease assessment in acute lymphoblastic leukaemia allows safe individualisation of chemotherapy and reduction of treatment toxicity (University of Bristol)

New businesses, commercial investment and adoption of new technology result from antigen-specific peptide immunotherapy development (University of Bristol)

Substantial changes in worldwide healthcare policy and the practice of joint replacement result from research into the failure rates of and systemic effects of metal-on-metal hip replacements (University of Bristol)

Translating research into novel immunotherapies delivers scientific and economic gains for the pharmaceutical/biotechnology sector in drug discovery (University of Bristol)

Use of aspirin and high dietary fibre to prevent and reduce deaths from bowel and other cancers, influencing global policy on cancer prevention and major public health campaigns (‘five-a-day’) (University of Bristol)

Biomedical informatics transforming the care of people with chronic diseases internationally (University of Dundee)

BNP as a Diagnostic and Risk Stratifying Test in Cardiology (University of Dundee)

Filaggrin – the major predisposing gene for atopic disease and a target for stratified therapeutic intervention (University of Dundee)

New Approaches to Drug and Chemical Safety Assessment (University of Dundee)

Spironolactone as a Treatment to extend life in Heart Failure Patients (University of Dundee)

The use of aspirin as a primary prophylaxis against cardiovascular events in patients with Diabetes (University of Dundee)

1. The Dermatology Life Quality Index: the leading patient–orientated dermatology outcome measure used worldwide (Cardiff University)

2. Cardiff-led research underpins new UK and International clinical treatment guidelines for the management of acquired haemophilia A (Cardiff University)

3. A New Standard of Care for Locally Advanced Prostate Cancer (Cardiff University)

4. Identification of MUTYH, the first recessive colorectal cancer gene, improves management of familial bowel cancer (Cardiff University)

5. Cardiff research yields evidence for benefits of sentinel node biopsy and spearheads training in the technique as a standard of care in breast cancer surgery (Cardiff University)

6. Identification of a novel drug resistance determinant resulting in global change of attitude and policy (Cardiff University)

7. Discovery and exploitation of fluorescent dyes in healthcare, drug discovery and life sciences (Cardiff University)

Personalised medicine in patients with Maturity Onset Diabetes of the Young (University of Exeter)

Stopping insulin; a life-changing therapeutic intervention for patients with neonatal diabetes (University of Exeter)

The plastics chemical Bisphenol A and its potential human health effects (University of Exeter)

Back to More 4* REF impact case studies